RxDoctor Payments Data

Angela Kelley, DO

Internal Medicine · Dubuque, IANPI 1881654473

Payments from drug & device makers

$983in general payments, 2019–2025

Across 63 payments — averaging $15.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$229
  • AbbVie$200
  • Novo Nordisk$94
  • AstraZeneca$66
  • Amgen$60
  • Lundbeck LLC$53
  • plus $281 from 10 others

What the payments were for

  • Food & beverage$983100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$983 in reported general payments places this provider in the 85th percentile of 583 internal medicine providers in Iowa.

See all internal medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$200,073
Medicare patients
349
Services billed
9,188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban198$168,324
JardianceEmpagliflozin99$120,720
OzempicSemaglutide99$111,876
MounjaroTirzepatide77$86,002
XareltoRivaroxaban49$53,729
JanuviaSitagliptin Phosphate40$49,152
LinzessLinaclotide43$35,150
FarxigaDapagliflozin Propanediol38$32,536
RybelsusSemaglutide16$23,439
Nurtec OdtRimegepant Sulfate13$22,544
TradjentaLinagliptin14$21,197
VraylarCariprazine Hcl12$16,770
MyrbetriqMirabegron33$15,182
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$11,426
Tresiba Flextouch U-100Insulin Degludec16$10,864

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$229$190,869211 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$26$150,167127 claims
Novo NordiskOzempic, Rybelsus$94$135,315115 claims
Lilly USA, LLCMounjaro$33$86,00277 claims
Johnson & JohnsonXarelto$15$53,72949 claims
AbbVieLinzess, Vraylar$200$51,92055 claims
AstraZenecaFarxiga, Symbicort$66$39,47957 claims
GSKArnuity Ellipta, Breo Ellipta, Anoro Ellipta$51$20,63173 claims
Astellas Pharma US IncMyrbetriq$35$15,18233 claims
AmgenCorlanor$60$6,56711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 583 internal medicine providers in Iowa.

Other internal medicine in Dubuque

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →